라니 테라퓨틱스(RANI)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.86 (+0.49%), 시가총액 $0.12B, 52주 최저~최고 $0.41 ~ $2.85.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111,
라니 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
라니 테라퓨틱스의 현재 주가는 $0.86 (+0.49%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
라니 테라퓨틱스의 시가총액은 약 $0.12B입니다.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and